Promising new treatment to help with bone marrow transplants
New stem cell therapy from Osiris Therapeutics proves helpful to bone marrow transplant procedures
A newly developed stem cell therapy called Prochymal has come as good news for those who have had or will have a bone marrow transplant at some point in their lives.
The therapy was developed to help fight a potentially fatal side effect that sometimes results from bone marrow transplants – “graft vs. host disease“. This disease occurs when foreign bone marrow attacks a patient’s body after transplantation.
Prochymal is still in the final stages of testing, but has been granted a preemptive approval since there are no other effective treatments for this condition.
While it has not been approved for widespread use in the U.S., the FDA has approved it for patients with the condition whose bodies have not responded well to steroids as a treatment.
When the approval of Prochymal by Health Canada was first announced, Osiris Therapeutics saw its stock trade at a higher price. This goes to show that not only is the stem cells industry revolutionary and helpful to patients, but profitable for companies as well.
Involved in the stem cells industry? Check out our Stem Cells USA & Regenerative Medicine Congress, taking place this September in Boston.